Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user experienced significant hair regrowth over eight months using topical minoxidil twice daily and 1mg oral finasteride daily. They also mentioned using a DHT blocker to aid regrowth.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The user has been using finasteride, ketoconazole shampoo, oral minoxidil, and minoxidil foam for hair loss but feels their hair is not as thick as desired. They have stopped using RU58841 due to lack of results and are concerned about hair miniaturization despite these treatments.

A user recommends using a microscope to assess hair density and track hair loss progress, finding it useful for evaluating treatment effectiveness, particularly with dutasteride and minoxidil. They advise against obsessing over hair loss and emphasize focusing on other meaningful life aspects.

The user experienced significant hair regrowth with topical finasteride, minoxidil, ketoconazole, and dermarolling, but later faced severe hair shedding after stopping dermarolling and reducing ketoconazole use. Suggestions included switching to oral treatments, resuming dermarolling, and considering lifestyle changes.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A user experienced significant hair regrowth using topical minoxidil, water-soluble pumpkin seed oil, and saw palmetto. Despite not using finasteride, the user reported reduced hair loss and increased hair growth, especially around the temples and beard.

The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.

Minoxidil use led to excessive eyebrow and forehead hair growth, prompting grooming advice like waxing, tweezing, and shaving. Some suggested reducing dosage or considering electrolysis for permanent hair removal.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

The conversation is about updates on Scube3 related to hair loss. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

The user is unhappy with their hair transplant results, feeling the hairline looks unnatural, but most commenters reassure them it looks good and natural. Some suggest styling changes or focusing on hair care routines.

A 31-year-old user shared progress pictures after 4 months on a hair loss routine. The routine includes microneedling twice a month, Hims Min/fin topical, and a collagen peptide supplement.

A dermatologist recommended PRP (Platelet Rich Plasma) and GFC (Growth Factor Concentrate) for pattern baldness, but online sources suggest they may not be effective. The user is seeking opinions on these treatments.

The user shared their 5-month progress using oral finasteride, topical minoxidil, and weekly dermarolling for hair loss. They expressed pride in their results, receiving positive feedback from others.

The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.

A user shared their aggressive hair loss treatment regimen, which includes daily use of Avodart (dutasteride) and Minoxidil, bi-weekly use of Davines Purifying shampoo, and almost daily use of Ducray Anaphase+ shampoo, along with supplements like vitamin D3, collagen, biotin, and zinc. They also use a dermastamp every 10 days and are considering a hair transplant for increased density, followed by a switch to finasteride and Minoxidil foam.

AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

The conversation is about hair regrowth progress using a combination of treatments: dutasteride, minoxidil, RU58841, ketoconazole, and monthly microneedling. The user reports that microneedling and topical minoxidil had the most impact on their hairline.

The user discusses their hair loss experience, exploring various hypotheses including thyroid levels, vitamin D, DHEA, nutritional deficiency, diabetes, seborrheic dermatitis, lack of nutrition to hair follicles, chronic inflammation, female pattern hair loss causes, cortisol, and prolactin levels. They are currently using finasteride, beta-sitosterol, and have tried topical dutasteride and microneedling therapy.

Pyrilitamide (KX-826) did not show significant improvement in hair count compared to placebo after 6 months. It's unclear if it can maintain hair at baseline.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.